Bio-Rad Laboratories, Inc. Q1 2026 Financial Results

Bio-Rad Laboratories, Inc. announced its financial results for the first quarter ended March 31, 2026. Despite facing challenging academic end markets and geopolitical conflicts, the company reported a 1.1% year-over-year sales increase, reaching $592.1 million. However, on a currency-neutral basis, sales decreased by 4.2%. The Life Science segment sales were flat year-over-year, with a 4.3% decrease on a currency-neutral basis, primarily due to challenges in the academic research market. The Clinical Diagnostics segment saw a 1.9% increase in sales, but a 4.1% decrease on a currency-neutral basis, influenced by regional conflicts. The company experienced a net loss of $527.1 million due to a change in the fair market value of its investment in Sartorius AG. Non-GAAP net income was $50.9 million. The company updated its full-year 2026 outlook, now expecting currency-neutral revenue to decline between 3.0% and grow 0.5%, with a non-GAAP operating margin of 10.0% to 12.0%. Free cash flow for the quarter was $78.1 million.